X
X
Total 667546 Results
| Label | Description | ILX | Version | Created CID | Modified Time | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Amperometric electrode recording protocol | ILX:0100560 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Amphetamine | Amphetamine is a chiral compound. The racemic mixture can be divided into its optical antipodes: levo- and dextro-amphetamine. Amphetamine is the parent compound of its own structural class, comprising a broad range of psychoactive derivatives, e.g., MDMA (Ecstasy) and the N-methylated form, methamphetamine. Amphetamine is a homologue of phenethylamine. Pharmacology: Amphetamine and dextroamphetamine, non-catechloamine sypathomimetic agents, are used in combination to treat attention-deficit hyperactivity disorder (ADHD) or narcolepsy. Adderall consists of equivalent amounts of amphetamine aspartate, amphetamine sulfate, dextroamphetamine saccharate, and dextroamphetamine sulfate. Mechanism of action: Amphetamines stimulate the release of norepinephrine from central adrenergic receptors. At higher dosages, they cause release of dopamine from the mesocorticolimbic system and the nigrostriatal dopamine systems. Amphetamine may also act as a direct agonist on central 5-HT receptors and may inhibit monoamine oxidase (MAO). In the periphery, amphetamines are believed to cause the release of noradrenaline by acting on the adrenergic nerve terminals and alpha- and beta-receptors. Modulation of serotonergic pathways may contribute to the calming affect. Drug type: Approved. Illicit. Small Molecule. Drug category: Adrenergic Agents. Adrenergic Uptake Inhibitors. Amphetamines. Central Nervous System Stimulants. Dopamine Agents. Dopamine Uptake Inhibitors. Sympathomimetics | ILX:0100561 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Amphetamine-Related Disorder | Disorders related or resulting from use of amphetamines (MeSH). | ILX:0100562 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Amphibia | ILX:0100563 | 5 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Amphiesmenoptera | ILX:0100564 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Amphotericin B | Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL in vitro. While Candida albicans is generally quite susceptible to amphotericin B, non-albicans species may be less susceptible. Pseudallescheria boydii and Fusarium sp. are often resistant to amphotericin B. The antibiotic is without effect on bacteria, rickettsiae, and viruses. Pharmacology: Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL in vitro. While Candida albicans is generally quite susceptible to amphotericin B, non-albicans species may be less susceptible. Pseudallescheria boydii and Fusarium sp. are often resistant to amphotericin B. The antibiotic is without effect on bacteria, rickettsiae, and viruses. Mechanism of action: Amphotericin B is fungistatic or fungicidal depending on the concentration obtained in body fluids and the susceptibility of the fungus. The drug acts by binding to sterols in the cell membrane of susceptible fungi with a resultant change in membrane permeability allowing leakage of intracellular components. Ergosterol, the principal sterol in the fungal cytoplasmic membrane, is the target site of action of amphotericin B and the azoles. Amphotericin B, a polyene, binds irreversibly to ergosterol, resulting in disruption of membrane integrity and ultimately cell death. Drug type: Approved. Investigational. Small Molecule. Drug category: Amebicides. Anti-Bacterial Agents. Antifungal Agents. Antiprotozoal Agents | ILX:0100565 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Ampicillin | Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic. (PubChem) Pharmacology: Ampicillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name penicillin" can either refer to several variants of penicillin available | ILX:0100566 | 0 | scicrunch | 01/01/1970 | scicrunch | 01/01/1970 | 0 | NeuroLex | troy sincomb | |
| Amplifier | Amplifiers are used in intracellular and extracellular recording, epithelial voltage clamps, specialty instruments for micro-pressure measurement and bio-potential discrimination, and work with electrodes and transducers. | ILX:0100567 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Amplitude | A physical monadic quality of occurent quality inhering in a bearer by virtue of the size of its maximum displacement from the 'normal' position, when periodic motion is taking place. | ILX:0100568 | 5 | scicrunch | 08/24/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Amprenavir | Amprenavir is a protease inhibitor used to treat HIV infection. Pharmacology: Amprenavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Amprenavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs. Mechanism of action: Amprenavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. Drug type: Approved. Small Molecule. Drug category: Anti-HIV Agents. Antibiotics, Antitubercular. HIV Protease Inhibitors | ILX:0100569 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Ampulla caudalis | Caudal dilation of the spinal cord central canal. In lower vertebrates, it represents the major route by which cerebral spinal fluid enters the blood stream. | ILX:0100570 | 9 | scicrunch | 11/30/2020 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Amsacrine | Aminoacridine derivative that is a potent intercalating antineoplastic agent. It is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in the treatment of solid tumors. It is frequently used in combination with other antineoplastic agents in chemotherapy protocols. It produces consistent but acceptable myelosuppression and cardiotoxic effects. (PubChem) Pharmacology: Amsacrine is an aminoacridine derivative that is a potent intercalating antineoplastic agent. It is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in the treatment of solid tumors. It is frequently used in combination with other antineoplastic agents in chemotherapy protocols. It produces consistent but acceptable myelosuppression and cardiotoxic effects. Mechanism of action: Amsacrine binds to DNA through intercalation and external binding. It has a base specificity for A-T pairs. Rapidly dividing cells are two to four times more sensitive to amsacrine than are resting cells. Amsacrine appears to cleave DNA by inducing double stranded breaks. Amsacrine also targets and inhibits topoisomerase II. Cytotoxicity is greatest during the S phase of the cell cycle when topoisomerase levels are at a maximum. Drug type: Approved. Small Molecule. Drug category: Antineoplastic Agents. Intercalating Agents | ILX:0100571 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Amydala of WHS11 | ILX:0100572 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Amygdala | Subcortical brain region lying anterior to the hippocampal formation in the temporal lobe and anterior to the temporal horn of the lateral ventricle in some species. It is usually subdivided into several groups. Functionally, it is not considered a unitary structure (MM). | ILX:0100573 | 14 | scicrunch | 06/23/2020 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Amygdala basolateral nuclear complex nonpyramidal PV basket cell | Multipolar nonpyramidal interneuron whose axon forms multiple synaptic contacts with the somata of numerous neighboring pyramidal cells. It is one of several parvalbumin-containing interneuronal subpopulations. | ILX:0100574 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Amygdala basolateral nuclear complex nonpyramidal PV chandelier cell | Multipolar nonpyramidal interneuron whose axon forms multiple synaptic contacts with the axon initial segments of numerous neighboring pyramidal cells. It is one of several parvalbumin-containing interneuronal subpopulations. | ILX:0100575 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Amygdala basolateral nuclear complex nonpyramidal SOM neuron | Somatostatin-containing nonpyramidal neuron whose axon forms synaptic contacts with the distal dendrites and spines of neighboring pyramidal cells. Although generally considered an interneuron, at least some of these cells have distant axonal projections to the substantia innominata or entorhinal cortex. A subpopulation expresses neuropeptide Y. | ILX:0100576 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Amygdala basolateral nuclear complex pyramidal neuron | These neurons make up ~80-85% of neurons in the basolateral nuclear complex of the amygdala. Unlike cortical pyramidal cells, they are not arranged with parellel apical dendrites but are randomly organized. | ILX:0100577 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Amygdala intercalated nuclei small spiny neuron | Small spiny principal neurons of the intercalated nuclei. These nuclei are clusters of neurons surrounding rostral portions of the basolateral nuclear complex. Some of these clusters are located adjacent to the external capsule or intermediate capsule (paracapsular intercalated nuclei). | ILX:0100578 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Amygdala lateral central nucleus medium spiny neuron | Medium-sized, multipolar, principal neuron found in lateral portions of the central nucleus. It has very spiny dendrites and closely resembles the medium spiny neuron of the adjacent striatum. | ILX:0100579 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
About
Base community for the SciCrunch.org infrastructure
Contact Us
X